check my math, but NuPathe's corporate presentation seems to indicate this is a multi-billion dollar income stream
per presentation, 1 and a 1/2 million migraine sufferers vomit during every migraine attack
the company seems to indicate 24 episodes per year are typical
rounding down to 20 episodes per year at their projected cost of $95 per patch indicates almost 3 BILLION PER YEAR
per presentation, 3 and a 1/2 million vomit on a regular basis during migraine attacks
that would indicate 6 and a 1/2 BILLION per year
yes, I think it's currently a little undervalued, whether you want to go by the current share count, or by possible diluted share count
FDA approval was expected. Now comes commercialization. No partner, inability to fund it internally and strong competition from new inhaled migraine drug (DHE) with better results that will be FDA approved later, but launch first. Nupathe's only option is buyout. I'm out with a small profit.